Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention

Simon D J Gibbs,* John O'Grady,^† John F Seymour,^‡ H Miles Prince§

Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrew's Place, East Melbourne, VIC 8006.

Correspondence: simongibbs02@yahoo.com.au

1. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005; 182: 413-415. <eMJA full text>
2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117.
3. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates [letter]. N Engl J Med 2005; 353: 99-102.
4. McCloskey EV, Dunn JA, Kanis JA, et al. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001; 113: 1035-1043.

Online responses are no longer available. Please refer to our instructions for authors page for more information.